Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07XXK
|
|||
| Former ID |
DNC003642
|
|||
| Drug Name |
6-(Biphenyl-2-sulfonyl)-2H-pyridazin-3-one
|
|||
| Synonyms |
CHEMBL72752; SCHEMBL6207186; BDBM16448; 6-phenylsulfonylpyridazin-2H-3-one, 10; Phenyl-Substituted Sulfonylpyridazinone, 8j
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H12N2O3S
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)C2=CC=CC=C2S(=O)(=O)C3=NNC(=O)C=C3
|
|||
| InChI |
1S/C16H12N2O3S/c19-15-10-11-16(18-17-15)22(20,21)14-9-5-4-8-13(14)12-6-2-1-3-7-12/h1-11H,(H,17,19)
|
|||
| InChIKey |
PICCQCWBQAQOHS-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aldose reductase (AKR1B1) | Target Info | Inhibitor | [1] |
| BioCyc | Methylglyoxal degradation III | |||
| Acetone degradation I (to methylglyoxal) | ||||
| KEGG Pathway | Pentose and glucuronate interconversions | |||
| Fructose and mannose metabolism | ||||
| Galactose metabolism | ||||
| Glycerolipid metabolism | ||||
| Metabolic pathways | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Fructose and Mannose Degradation | |||
| Pyruvate Metabolism | ||||
| Pterine Biosynthesis | ||||
| Glycerolipid Metabolism | ||||
| Galactose Metabolism | ||||
| WikiPathways | Metapathway biotransformation | |||
| Polyol Pathway | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.